首页> 美国卫生研究院文献>Applied and Environmental Microbiology >Fermentative Production of Thymidine by a Metabolically Engineered Escherichia coli Strain
【2h】

Fermentative Production of Thymidine by a Metabolically Engineered Escherichia coli Strain

机译:代谢工程大肠杆菌菌株的胸苷发酵生产

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Thymidine is an important precursor in the production of various antiviral drugs, including azidothymidine for the treatment of AIDS. Since thymidine-containing nucleotides are synthesized only by the de novo pathway during DNA synthesis, it is not easy to produce a large amount of thymidine biologically. In order to develop a host strain to produce thymidine, thymidine phosphorylase, thymidine kinase, and uridine phosphorylase genes were deleted from an Escherichia coli BL21 strain to develop BLdtu. Since the genes coding for the enzymes related to the nucleotide salvage pathway were disrupted, BLdtu was unable to utilize thymidine or thymine, and thymidine degradation activity was completely abrogated. We additionally expressed T4 thymidylate synthase, T4 nucleotide diphosphate reductase, bacteriophage PBS2 TMP phosphohydrolase, E. coli dCTP deaminase, and E. coli uridine kinase in the BLdtu strain to develop a thymidine-producing strain (BLdtu24). BLdtu24 produced 649.3 mg liter−1 of thymidine in a 7-liter batch fermenter for 24 h, and neither thymine nor uridine was detected. However, the dUTP/dTTP ratio was increased in BLdtu24, which could lead to increased double-strand breakages and eventually to cell deaths during fermentation. To enhance thymidine production and to prevent cell deaths during fermentation, we disrupted a gene (encoding uracil-DNA N-glycosylase) involved in DNA excision repair to suppress the consumption of dTTP and developed BLdtug24. Compared with the thymidine production in BLdtu24, the thymidine production in BLdtug24 was increased by ∼1.2-fold (740.3 mg liter−1). Here, we show that a thymidine-producing strain with a relatively high yield can be developed using a metabolic engineering approach.
机译:胸苷是生产各种抗病毒药物(包括用于治疗艾滋病的叠氮胸苷)的重要前体。由于含胸苷的核苷酸仅在DNA合成过程中通过从头途径合成,因此生物学上生产大量胸苷并不容易。为了发育宿主菌株以产生胸苷,从大肠杆菌BL21菌株中删除了胸苷磷酸化酶,胸苷激酶和尿苷磷酸化酶基因以产生BLdtu。由于编码与核苷酸挽救途径相关的酶的基因被破坏,BLdtu无法利用胸苷或胸腺嘧啶,胸腺嘧啶核苷的降解活性被完全废除。我们还在BLdtu菌株中表达了T4胸苷酸合酶,T4核苷酸二磷酸还原酶,噬菌体PBS2 TMP磷酸水解酶,大肠杆菌dCTP脱氨酶和大肠杆菌尿苷激酶,以开发产生胸苷的菌株(BLdtu24)。 BLdtu24在7升分批发酵罐中产生649.3 mg升-1的胸腺嘧啶核苷达24 h,未检测到胸腺嘧啶和尿苷。但是,BLdtu24中的dUTP / dTTP比值增加,这可能导致双链断裂增加,并最终导致发酵过程中细胞死亡。为了提高胸苷的产生并防止发酵过程中的细胞死亡,我们破坏了参与DNA切除修复的基因(编码尿嘧啶DNA N-糖基化酶)以抑制dTTP的消耗并开发了BLdtug24。与BLdtu24中的胸苷产量相比,BLdtug24中的胸苷产量增加了约1.2倍(740.3 mg升 -1 )。在这里,我们表明可以使用代谢工程方法开发出具有较高产量的胸苷生产菌株。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号